From MedPage Today:
- Clinical Focus in MS: Novel Approaches to Progressive Disease. Although the drug development pipeline still contains numerous products intended for patients with relapsing-remitting multiple sclerosis (RRMS), the consensus among clinicians is that relapses can be effectively squelched in nearly all RRMS patients with the dozen or so currently approved therapies.
- Clinical Focus in Renal Cell Carcinoma: Indolent Disease Tx. A select subset of patients with metastatic renal cell carcinoma (mRCC) can safely remain in observation for a year or longer, avoiding treatment-related toxicity.
- When Primary Care Is Primarily Caring. When I started my internal medicine residency, I was pretty sure I was going to rock this primary care thing. I knew the drugs for hypertension, the guidelines for diabetes management, and depression management seemed like nothing more than an algorithm.
- Anti-IL-6 Shows Promise in Lupus. Promising clinical responses were seen among patients with active systemic lupus erythematosus treated with an interleukin (IL)-6 monoclonal antibody.
